We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Jam factory

15 Apr 2021 By Robert Cyran

The U.S. scientific device maker looks like it is overpaying for PPD given its return on investment will be less than 5% in a few years’ time. But a decade of deals shows PPD’s buyers benefiting from a trend for clinical trials to be outsourced. That may be true again this time.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)